Regeneron Pharmaceuticals, Inc. (REGN) — 10-Q Filings

10-Q Filings (7)

• Regeneron Pharmaceuticals Files Q1 2026 10-Q Report — Apr 29, 2026 Risk: low
  Regeneron Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2026. The filing includes financial statements, certific
• Regeneron's Collaboration Gains Offset EYLEA Sales Dip, Net Income Rises — Oct 28, 2025 Risk: medium
  Regeneron Pharmaceuticals, Inc. reported a mixed financial performance for the nine months ended September 30, 2025. Net product sales decreased by 17.6% to $4.
• Regeneron Posts Modest Q2 Revenue Growth Amidst Steady Product Sales — Aug 1, 2025 Risk: medium
  REGENERON PHARMACEUTICALS, INC. reported total revenue of $3.15 billion for the second quarter of 2025, a slight increase from $3.08 billion in the prior-year q
• Regeneron Files Q1 2025 10-Q — Apr 29, 2025 Risk: low
  Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the fi
• Regeneron Pharmaceuticals Q3 2024 Update — Oct 31, 2024 Risk: low
  Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported significant product sales and collaboration revenu
• Regeneron Files Q2 2024 10-Q — Aug 1, 2024 Risk: low
  Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the sec
• Regeneron Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — May 2, 2024 Risk: low
  REGENERON PHARMACEUTICALS, INC. (REGN) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Regeneron Pharmaceuticals, Inc. filed a 10-Q report for the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX